Susquehanna International Group
ALXN

Susquehanna International Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Susquehanna International Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-319,100
Closed -$58.6M – 14110
2021
Q2 		$58.6M Buy
319,100
+41,000
+15% +$7.04M 0.01% 1093
2021
Q1 		$42.5M Sell
278,100
-193,500
-41% -$29.9M 0.01% 1228
2020
Q4 		$73.7M Buy
471,600
+52,400
+13% +$6.73M 0.01% 803
2020
Q3 		$48M Sell
419,200
-45,300
-10% -$4.89M 0.01% 878
2020
Q2 		$52.1M Sell
464,500
-154,400
-25% -$16.4M 0.01% 809
2020
Q1 		$55.6M Buy
618,900
+177,300
+40% +$17.4M 0.02% 609
2019
Q4 		$47.8M Buy
441,600
+26,900
+6% +$2.88M 0.01% 834
2019
Q3 		$40.6M Sell
414,700
-51,300
-11% -$5.78M 0.01% 858
2019
Q2 		$61M Buy
466,000
+158,100
+51% +$20.4M 0.02% 596
2019
Q1 		$41.6M Sell
307,900
-9,100
-3% -$1.13M 0.02% 725
2018
Q4 		$30.9M Sell
317,000
-245,100
-44% -$29M 0.01% 818
2018
Q3 		$78.1M Sell
562,100
-11,900
-2% -$1.49M 0.03% 519
2018
Q2 		$71.3M Sell
574,000
-592,500
-51% -$69.2M 0.02% 522
2018
Q1 		$130M Buy
1,166,500
+731,200
+168% +$87.4M 0.05% 312
2017
Q4 		$52.1M Sell
435,300
-126,700
-23% -$15.4M 0.02% 677
2017
Q3 		$78.8M Sell
562,000
-34,400
-6% -$4.67M 0.03% 473
2017
Q2 		$72.6M Buy
596,400
+280,000
+88% +$32.6M 0.03% 452
2017
Q1 		$38.4M Sell
316,400
-379,800
-55% -$49M 0.02% 689
2016
Q4 		$85.2M Buy
696,200
+516,800
+288% +$63.2M 0.04% 375
2016
Q3 		$22M Sell
179,400
-152,600
-46% -$19.6M 0.01% 953
2016
Q2 		$38.8M Sell
332,000
-74,700
-18% -$10.6M 0.02% 614
2016
Q1 		$56.6M Buy
406,700
+35,500
+10% +$5.21M 0.03% 481
2015
Q4 		$70.8M Buy
371,200
+92,700
+33% +$16.2M 0.03% 468
2015
Q3 		$43.6M Sell
278,500
-43,900
-14% -$8.01M 0.02% 698
2015
Q2 		$58.3M Buy
322,400
+162,200
+101% +$28M 0.02% 617
2015
Q1 		$27.8M Sell
160,200
-164,100
-51% -$29.7M 0.01% 997
2014
Q4 		$60M Buy
324,300
+56,100
+21% +$10.4M 0.02% 633
2014
Q3 		$44.5M Buy
268,200
+14,400
+6% +$2.36M 0.02% 813
2014
Q2 		$39.7M Sell
253,800
-123,900
-33% -$19.6M 0.02% 852
2014
Q1 		$57.5M Sell
377,700
-320,600
-46% -$51M 0.03% 558
2013
Q4 		$92.9M Sell
698,300
-29,400
-4% -$3.53M 0.04% 376
2013
Q3 		$84.5M Buy
727,700
+251,300
+53% +$27.6M 0.04% 361
2013
Q2 		$43.9M Buy
+476,400
New +$45.9M 0.03% 625

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Susquehanna International Group's ALXN Position: Q3 2021 in Review

Susquehanna International Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 81,039 shares — an estimated $14.9M sold.

Susquehanna International Group first reported a position in ALXN in Q2 2013 and held it in 32 quarters. The position peaked at $78.8M in Q1 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Susquehanna International Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Susquehanna International Group sold 81,039 Alexion Pharmaceuticals shares in Q3 2021, an estimated $14.9M.
  • Susquehanna International Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 32 quarters.
  • Susquehanna International Group's Alexion Pharmaceuticals position peaked at $78.8M in Q1 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Susquehanna International Group's 13F filing for Q3 2021, filed 15 Nov 2021.